India set for new study on spurious drugs
This article was originally published in Scrip
Executive Summary
India continues to move towards improved regulatory oversight in the pharmaceutical segment. It has now initiated steps for a new study on spurious drugs and plans an expansion in the number of adverse drug reactions (ADR) monitoring centres in the country.